

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD

RIMFROST AS
Petitioner

v.

AKER BIOMARINE ANTARCTIC AS
Patent Owner

CASE NO: IPR2018-01730

U.S. Patent No. 9,072,752 B2

**Declaration of Dr. Nils Hoem in Support of Patent Owner's Response
and Motion to Amend**

TABLE OF CONTENTS

I.	Introduction.....	4
A.	Qualifications.....	5
B.	Legal Standards.....	16
II.	RESPONSE TO GROUNDS FOR INSTITUTION IN IPR.....	24
A.	‘752 Patent Claims and Basis for IPR.....	24
B.	Claim Construction.....	27
C.	Analysis.....	30
1.	Introduction.....	30
2.	Prior Art.....	36
a.	Catchpole (Ex. 1009).....	36
b.	Enzymotec (Ex. 1048).....	45
c.	Sampalis II (Ex. 1013).....	46
d.	Grynbaum (Ex. 1039).....	46
e.	Randolf (Ex. 1011).....	47
f.	Fricke 1984 and 1986 (Ex. 1010 and Ex. 2006).....	48
3.	Ground 1 Analysis – Claims 1, 5-6 and 11 are not anticipated by Catchpole.....	51
4.	Ground 2 Analysis – Claims 4, 7, 12 and 13 are not obvious over the combination of Catchpole and Sampalis II.....	53
5.	Ground 3 Analysis – Claims 8-10 are not obvious over the combination of Catchpole, Grynbaum and Randolf.....	58
6.	Ground 4 Analysis – Claims 1-3, 5, 6 and 11 are not obvious over the combination of Catchpole and Enzymotec.....	60
7.	Ground 5 Analysis – Claims 14-16 and 20 are not obvious over the combination of Catchpole, Enzymotec and Sampalis II.....	67
8.	Ground 6 Analysis – Claims 17-19 are not obvious over the combination of Catchpole, Enzymotec, Sampalis II, Grynbaum and Randolf.....	72
III.	SUPPORT FOR MOTION TO AMEND.....	74
A.	SUPPORT IN THE ORIGINAL DISCLSOURE FOR THE CONDITIONAL PROPOSED AMENDED CLAIMS.....	76
1.	Substitute Independent Claims 21 and 28.....	76
2.	Dependent Claims 22-27 and 29.....	79
3.	Claim Construction.....	80
4.	Patentability of the proposed substitute claims over the prior art.....	81

a.	Art at Issue in This Proceeding	81
b.	The Material Prior Art at Issue During Prosecution.....	89
IV.	Conclusion	90

I. Introduction

I, Dr. Nils Hoem, state as follows:

1. I have been asked by counsel for Petitioner Aker BioMarine AS to provide an expert declaration in this action. I am currently employed by Aker BioMarine AS.

2. I have reviewed U.S. Patent 9,072,752 (hereinafter ‘752 patent; Ex. 1001) and the claims contained therein. It is my understanding that the ‘752 patent contains claims to polar krill oil containing greater than 40% phosphatidylcholine and greater than 5% ether phospholipids. Additional limitations define krill oil compositions with higher amounts of phosphatidylcholine and ether phospholipids, specific amounts of omega-3 fatty acids, specific astaxanthin ester content and to the species of krill, *Euphausia superba*.

3. I have been asked to provide analysis and expert opinions on the following: whether the combination of references cited in this proceeding render claims of the ‘752 patent anticipated or obvious.

4. In connection with providing my opinions, I have further been asked to provide an overview of the technology of the ‘752 patent and state of the art that existing before the ‘752 patent was filed.

A. Qualifications

5. I am a licensed pharmacist with master and doctorate degrees in pharmacology. I was Associate Professor at Oslo University from 1989-2002 and European Director of Pharmacokinetics, Statistics and Data-Management at MDS Pharma Services, Hamburg Germany from 2004 to 2007. I am now Chief Scientist at Aker BioMarine. My educational background comprises skills in general, organic, analytic and biological chemistry in combination with his work at Aker BioMarine during the last 10 years have provided general and specialized insight into the complex composition of krill oil as well as the raw materials from which it has been extracted. In capacity of leading product development at Aker BioMarine, I have substantial theoretical and practical insight into extraction, fractionation and purification of krill oil and krill lipids. A more detailed account of my work experience, publications, and other qualifications is listed in my Curriculum Vitae, attached as Exhibit 1.

6. I am being compensated by my normal salary for Aker BioMarine AS. My compensation is not contingent on the conclusions I reach in my expert report.

7. I have reviewed and considered, in the preparation of this report, the documents below.

EXHIBIT NO.	EXHIBIT DESCRIPTION
-------------	---------------------

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.